X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

RB invests $25 mn to set up new Reckitt Global Hygiene Institute

Content Team by Content Team
20th July 2020
in Drug Development, Press Statements
RB invests $25 mn to set up new Reckitt Global Hygiene Institute

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

RB is investing $25 million to set up the Reckitt Global Hygiene Institute (RGHI) which is a research and innovation hub that will bridge epidemiology, public health, and behavioural insights to generate practical, high-quality scientific research that leads to enduring behaviour change.

“The COVID-19 pandemic has pushed public health to the top of the global agenda. At RB, we see the need for a new paradigm that brings together the highest quality scientific based evidence and informed public health recommendations to generate large-scale behaviour change for a cleaner, healthier world,” said Laxman Narasimhan, CEO, RB.

“Today we’re announcing our commitment to convene a group of multi-disciplinary experts who, like us, believe real change on a global scale is within reach if we translate science-based evidence and consumer behavioural insights into sustainable hygienic practices that can be adopted globally. This ambitious goal is the result of our belief that the highest quality hygiene is a right and not a privilege,” he added.

The company’s commitment to global hygiene research and education includes the formation of an Expert Panel with to guide these research efforts at leading academic institutions around the world.

The creation of a Global Hygiene Institute with physical infrastructure, with a governing board will be supported by full-time staff, ongoing research, and education programming driven by expert researchers and educators.

Through the establishment of a fellowship program with leading universities, RGHI will generate practical, informed public health research and recommendations that champion global hygiene as the foundation of health. The Governing Board will determine specific areas for research and will work with the Expert Panel to award the fellowships to promising early career academics, who will become Reckitt Fellows. In addition to the fellowships, the Institute will award grants to institutions for open, collaborative, cross-functional research. The Expert Panel will further define the parameters of these awards.

The Governing Board and Expert Panel include Professor Peter Piot, Director of the London School of Hygiene & Tropical Medicine, Dame Sally Davies, Master of Trinity College, Cambridge, Professor Feng Cheng, Research Center for Public Health, Tsinghua University School of Medicine, Tsinghua, Dr. Randeep Guleria, Director, All India Institute of Medical Sciences (AIIMS), Professor Dr. Albert Ko, Department Chair and Professor of Epidemiology, Yale School of Medicine and Professor Teo Yik Ying, Dean, Saw Swee Hock School of Public Health, National University of Singapore.

Previous Post

Heron Therapeutics initiates phase 2 GUARDS-1 study of Cinvanti to treat COVID-19

Next Post

IDEAYA Biosciences meets clinical protocol criteria for cohort expansion in skin melanoma for phase 2 GNAQ/11 basket trial

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
biologic drug formulation stability
Drug Development

Breakthroughs in Biologic Drug Formulation Stability

27th September 2025
Next Post
Regeneron, Intellia to develop CRISPR/Cas9-based treatments

IDEAYA Biosciences meets clinical protocol criteria for cohort expansion in skin melanoma for phase 2 GNAQ/11 basket trial

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In